Etrasimod Significantly Improves Atopic Dermatitis in Phase 2b Trial
Etrasimod, an investigational drug for moderate to severe atopic dermatitis, demonstrated statistically significant improvements in a phase 2b clinical trial, according to a study presented at AAD VMX 2021.
Press Release
New Treatment for Moderate to Severe Atopic Dermatitis Shows Promising Long-Term Results
Dec 09, 2022 View All Press Releases